Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Pharmacotherapy

Optimal blockade of the renin–angiotensin–aldosterone system

Nature Reviews Cardiology volume 10, pages 183–184 (2013)Cite this article

Subjects

Inhibition of the renin–angiotensin–aldosterone system (RAAS) is a successful therapy for hypertension, heart failure, and renal insufficiency. Overdosing of RAAS inhibitors is occasionally observed when several agents are used together, and can cause adverse events such as hypotension, hyperkalaemia, and renal failure. We advocate optimal, rather than complete, RAAS blockade.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Makani, H., Bangalore, S., Desouza, K. A., Shah, A. & Messerli, F. H. Efficacy and safety of dual blockade of the renin–angiotensin system: meta-analysis of randomised trials. BMJ 346, f360 (2013).

    Article  Google Scholar 

  2. Oparil, S. et al. Efficacy and safety of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370, 221–229 (2007).

    Article  CAS  Google Scholar 

  3. Fisher, N. D., Danser, A. H., Nussberger, J., Dole, W. P. & Hollenberg, N. K. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 117, 3199–3205 (2008).

    Article  CAS  Google Scholar 

  4. Parving, H. H. et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433–2446 (2008).

    Article  CAS  Google Scholar 

  5. European Medicines Agency. European Medicines Agency recommends new contraindications and warnings for aliskiren-containing medicines [online], (2012).

  6. Whitbeck, M. G. et al. Increased mortality among patients taking digoxin—analysis from the AFFIRM study. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehs348.

  7. Juurlink, D. N. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543–551 (2004).

    Article  CAS  Google Scholar 

  8. Tanimoto, K. et al. Angiotensinogen-deficient mice with hypotension. J. Biol. Chem. 269, 31334–31337 (1994).

    CAS  PubMed  Google Scholar 

  9. Ménard, J., Campbell, D. J., Azizi, M. & Gonzales, M. F. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 96, 3072–3078 (1997).

    Article  Google Scholar 

  10. Parving, H. H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204–2213 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Angiology and Hypertension, Department of Internal Medicine, Centre hospitalier universitaire vaudois (CHUV), NES-6027, Lausanne, CH-1011, Switzerland

    Jürg Nussberger

  2. Clinique de médecine, Hôpital Fribourgeois, Chemin des Pensionnats 2, Fribourg, CH-1708, Switzerland

    Jürgen Bohlender

Authors
  1. Jürg Nussberger
    View author publications

    Search author on:PubMed Google Scholar

  2. Jürgen Bohlender
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Jürg Nussberger.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nussberger, J., Bohlender, J. Optimal blockade of the renin–angiotensin–aldosterone system. Nat Rev Cardiol 10, 183–184 (2013). https://doi.org/10.1038/nrcardio.2013.28

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrcardio.2013.28

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing